The combination approach of rosuvastatin and ezetimibe in post-stent patients

Shirlin M. S1*, Vignesh R1, Madhumitha B2

1Clinical Pharmacist, Kauvery hospital, Heart city, Trichy, Tamil Nadu

2Group Clinical Pharmacist, Kauvery Hospital, Trichy, Tamil Nadu

*Correspondence

Abstract

Dyslipidemia is a key risk factor for coronary artery disease, especially in patients who have undergone coronary stenting. The Cardiological Society of India recommends strict LDL cholesterol control, with very low targets in high-risk patients. Rosuvastatin is a strong statin that lowers cholesterol and helps stabilize plaques. However, statins alone may not always achieve target levels. Adding Ezetimibe, which reduces cholesterol absorption from the intestine, provides additional LDL reduction. This combination therapy is especially useful after stent placement, where lowering cholesterol and preventing clot formation are critical. Along with antiplatelet therapy, it helps improve vessel healing and reduces the risk of future cardiac events. Thus, combining Rosuvastatin and Ezetimibe is an effective and guideline-recommended approach for better lipid control and improved outcomes in high-risk and post-stent patients.

Introduction

Cardiovascular disease remains one of the leading causes of morbidity and mortality worldwide. In India, the burden of dyslipidemia and coronary artery disease (CAD) is rapidly increasing. The Cardiological Society of India recommends aggressive lipid-lowering strategies in high-risk and post-percutaneous coronary intervention (PCI) patients. The combination drug Rosuvastatin and Ezetimibe, is widely used to achieve optimal LDL-cholesterol reduction in such high-risk populations.

Mechanism of action

Rosuvastatin is a potent statin that:

  • Inhibits HMG-CoA reductase
  • Reduces hepatic cholesterol synthesis
  • Up-regulates LDL receptors
  • Enhances LDL clearance from plasma

Clinical impact

  • LDL reduction: 50–60%
  • Plaque stabilization
  • Anti-inflammatory effects
  • Endothelial protection
  • Reduction in major cardiovascular events

Ezetimibe – Cholesterol Absorption Inhibitor

Ezetimibe acts at the intestinal level by blocking the NPC1L1 transporter, which is responsible for cholesterol absorption.

Effects

  • Reduces intestinal cholesterol absorption
  • Decreases hepatic cholesterol stores
  • Further reduces LDL by 15–25%

Combination benefit

Statin + Ezetimibe therapy provides synergistic LDL reduction, helping patients reach guideline-recommended targets. The combination allows for a lower dose of each individual agent to achieve the same changes in the lipid panel.

CSI guideline recommendations

According to the Cardiological Society of India lipid management recommendations:

  • LDL Targets: Very high risk (Post-MI / Post-PCI) <55 mg/Dl, High risk <70 mg/Dl
  • For patients who do not reach LDL goals with statins alone, addition of Ezetimibe is recommended.

Thus, Rosuvastatin and Ezetimibe are ideal in:

  • Post-angioplasty patients
  • Diabetes with CAD
  • High-risk dyslipidemia
  • Secondary prevention of cardiovascular disease

Role after coronary stenting: Patients undergoing Coronary Stent Implantation require aggressive secondary prevention therapy.

Treatment includes

Antiplatelet therapy

Following stent placement, patients receive Dual Antiplatelet Therapy (DAPT):

Purpose

  • Prevent platelet aggregation
  • Avoid stent thrombosis

Antiplatelet Interaction with Endothelial Healing after stent placement

  • The stent is embedded into the arterial wall.
  • Endothelial cells grow over the stent struts (endothelialization).
  • Antiplatelet drugs prevent thrombus formation during this healing period.

Antiplatelets

  • Act systemically in platelets
  • Prevent clot formation on the stent surface
  • Support safe endothelial healing

They are not absorbed into endothelial cells but rather inhibit platelet activation circulating in blood.

Importance of statins after stenting

Statins provide multiple benefits beyond lipid lowering:

  • Pleiotropic Effects
  • Improve endothelial function
  • Reduce vascular inflammation
  • Stabilize atherosclerotic plaques
  • Decrease restenosis risk

These benefits make high-intensity statin therapy mandatory after PCI.

Clinical advantages of combining Rosuvastatin & Ezetimibe:

  • Powerful LDL reduction (>65%)
  • Helps achieve CSI LDL targets
  • Reduces cardiovascular risk
  • Improves endothelial function
  • Supports plaque stabilization
  • Convenient single-pill combination

Conclusion

Aggressive lipid-lowering therapy is essential in patients with coronary artery disease and post-stent implantation. According to the Cardiological Society of India guidelines, combination therapy with a high-intensity statin and Ezetimibe is recommended when LDL targets are not achieved with statins alone. The fixed-dose combination rosuvastatin and ezetimibe offers an effective therapeutic option providing superior LDL reduction and improved cardiovascular outcomes in high-risk patients.

References

  1. Cardiological Society of India. Lipid Management Guidelines for Indian Population. J Assoc Physicians India. 2020;68(Suppl):7–15.
  2. Grundy SM, et al. 2018 AHA/ACC Guideline on the Management of Blood Cholesterol. Circulation. 2019;139(25):e1082–e1143.
  3. European Society of Cardiology; European Atherosclerosis Society. 2019 ESC/EAS Guidelines for the management of dyslipidaemias. Eur Heart J. 2020;41(1):111–188.
  4. Cannon CP, et al. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes (IMPROVE-IT). N Engl J Med. 2015;372:2387–2397.
  5. American College of Cardiology; American Heart Association. Guideline for Dual Antiplatelet Therapy in Coronary Artery Disease. Circulation. 2016;134:e123–e155.

Nightingale Journals

Kauvery Hospital
Find Doctor
Book Appointment